Category: Support
Johnson & Johnson’s Dual Control Campaign: A New Chapter for IBD Dreams
Johnson & Johnson’s new “Dual Control” campaign addresses the challenge many IBD patients face: balancing health management with pursuing life dreams. The campaign emphasizes deeper disease control and patient-healthcare team partnerships to help people with IBD reclaim their ambitions.
Breaking the Silence: Why Sharing Your IBD Story Creates Hope
Breaking the silence around IBD experiences creates ripple effects that extend far beyond individual healing. When we share our stories, we build understanding, reduce isolation, and create the support networks our community desperately needs.
Japan’s IBD Crisis: What Rising Rates Mean for Us
New research showing a 40% increase in IBD cases in Japan offers crucial insights into environmental factors affecting our community. Here’s what this trend means for patients and families worldwide.
Why Staying Informed Could Change Your IBD Journey Forever
Living with IBD means navigating constant changes in treatment options and best practices. Staying informed isn’t just about understanding medications—it’s about becoming an empowered partner in your healthcare journey and unlocking better outcomes for your life with IBD.
Curcumin for IBD: Could This Golden Spice Transform Your Gut?
New research reveals curcumin’s potential for supporting gut health through anti-inflammatory effects and microbiome balance. Here’s what IBD patients should know about this promising natural compound and how to discuss it with your healthcare team.
The Hidden Power of Food: Transforming Your IBD Journey One Bite at a Time
New research reveals how strategic food choices might help manage IBD symptoms and reduce flare risk. While diet alone isn’t a cure, understanding the connection between what we eat and inflammation offers hope and practical tools for better disease management.
A $36 Billion Promise: What IBD Treatment Growth Means for You
The IBD treatment market is projected to grow from $25.5 billion to nearly $36 billion by the early 2030s, reflecting unprecedented investment in personalized medicine and innovative therapies. This growth represents hope for better treatment options and outcomes for the millions living with Crohn’s disease and ulcerative colitis.
Should You Stop Anti-TNF Therapy in Remission? What New Research Tells Us
New research reveals that stopping anti-TNF therapy during IBD remission may not lead to immediate relapse, but subtle inflammatory markers suggest the disease might still be active beneath the surface. This has important implications for treatment decisions and long-term outcomes.
AI-Powered Hope: Personalized Nutrition for IBD Becomes Reality
University of Ottawa researchers have developed an AI-powered tool that creates personalized nutrition plans for IBD patients based on individual genetics, gut bacteria, and health history. This breakthrough could transform how we approach dietary management, moving beyond generic advice to truly individualized care that adapts to each person’s unique biology and symptoms.
Global IBD Registry Network: Turning Your Story Into Medical Progress
A groundbreaking Global IBD Registry Network is connecting patient data worldwide to accelerate research and improve personalized treatment options. This initiative transforms isolated medical records into powerful insights that could revolutionize IBD care for everyone in our community.
